New England Research & Management Inc. acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,545 shares of the medical instruments supplier's stock, valued at approximately $354,000.
Other large investors have also made changes to their positions in the company. Bank of Jackson Hole Trust bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth approximately $25,000. Sierra Ocean LLC acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at $29,000. REAP Financial Group LLC lifted its position in Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 55 shares during the period. Picton Mahoney Asset Management boosted its stake in Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after buying an additional 54 shares in the last quarter. Finally, Nexus Investment Management ULC bought a new stake in Becton, Dickinson and Company in the 1st quarter valued at $34,000. Institutional investors and hedge funds own 86.97% of the company's stock.
Insider Buying and Selling
In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president now directly owns 4,575 shares of the company's stock, valued at approximately $783,194.25. The trade was a 20.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 479 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the sale, the executive vice president now owns 4,887 shares of the company's stock, valued at approximately $964,107.36. This represents a 8.93% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by corporate insiders.
Becton, Dickinson and Company Price Performance
BDX traded down $2.09 during trading on Tuesday, hitting $170.01. The company's stock had a trading volume of 3,781,553 shares, compared to its average volume of 1,987,247. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $48.73 billion, a price-to-earnings ratio of 32.45, a price-to-earnings-growth ratio of 1.30 and a beta of 0.25. The firm's 50 day moving average price is $181.67 and its two-hundred day moving average price is $212.31. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The business had revenue of $5.27 billion during the quarter, compared to analysts' expectations of $5.35 billion. During the same period in the previous year, the business posted $3.17 earnings per share. The firm's revenue for the quarter was up 4.5% compared to the same quarter last year. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.45%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio is currently 79.39%.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on BDX. Barclays reduced their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a report on Tuesday, June 3rd. Raymond James Financial cut shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Wall Street Zen lowered Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Stifel Nicolaus cut their target price on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group cut Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target on the stock. in a research report on Friday, May 2nd. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus price target of $219.22.
Check Out Our Latest Stock Report on Becton, Dickinson and Company
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Read More
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
